WO2004085603A1 - The use of n-acetyl glucosamine as additive in beer and beer comprising n-acetyl glucosamine - Google Patents

The use of n-acetyl glucosamine as additive in beer and beer comprising n-acetyl glucosamine Download PDF

Info

Publication number
WO2004085603A1
WO2004085603A1 PCT/CN2004/000277 CN2004000277W WO2004085603A1 WO 2004085603 A1 WO2004085603 A1 WO 2004085603A1 CN 2004000277 W CN2004000277 W CN 2004000277W WO 2004085603 A1 WO2004085603 A1 WO 2004085603A1
Authority
WO
WIPO (PCT)
Prior art keywords
beer
acetylglucosamine
acceptable derivative
test
acetyl glucosamine
Prior art date
Application number
PCT/CN2004/000277
Other languages
French (fr)
Chinese (zh)
Inventor
Qiwang Xu
Junkang Liu
Zetao Yuan
Original Assignee
Third Military Medical University, Chinese People's Liberation Army, P.R. Of China
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Third Military Medical University, Chinese People's Liberation Army, P.R. Of China filed Critical Third Military Medical University, Chinese People's Liberation Army, P.R. Of China
Publication of WO2004085603A1 publication Critical patent/WO2004085603A1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12CBEER; PREPARATION OF BEER BY FERMENTATION; PREPARATION OF MALT FOR MAKING BEER; PREPARATION OF HOPS FOR MAKING BEER
    • C12C5/00Other raw materials for the preparation of beer
    • C12C5/02Additives for beer

Definitions

  • the present invention relates to the use of N-acetylglucosamine or an acceptable derivative thereof as an additive in beer, beer containing N-acetylglucosamine or an acceptable derivative thereof and a method for preparing beer.
  • the inventors discovered by accident in research work that when N-acetylglucosamine or an acceptable derivative of alcoholic products was added to beer in an appropriate ratio and drunk, the crowd test showed that the symptoms of dizziness were significantly reduced, and the drunken reaction did not occur. Or after drinking more Delayed occurrence, and can effectively smooth the subsequent drunk reactions after drinking beer, such as thirst, poor language expression, and general discomfort such as general weakness.
  • the inventors established a model of biological wave growth in the study of biological wave theory, and further studied the molecular mechanism of biological wave growth, and proposed the principle of slightly heterogeneous changes in the biological wave of a biological organism.
  • the speed of biological wave changes is fast or slow, depending on the degree of change in the external environment.
  • the internal environment changes rapidly, causing micro-heterogeneity to occur, causing an imbalance between the body and the environment, causing local damage or systemic poisoning symptoms.
  • the occurrence of such damage and poisoning symptoms is analyzed from the perspective of molecular biology. It is because proteins, especially various enzymes, have unstable functions or even loss of functions under changed conditions, especially in the presence of temperature changes and microbial metabolites. .
  • N-acetylglucosamine as a biological wave regulatory factor, can stabilize the oscillation of macromolecular substances, keep the physiological oscillations ongoing, slow down and repel the effects of adverse factors in the body, and thus maintain proteins, especially various enzymes. Similar physiological functions and reduce drinking damage.
  • Another object of the present invention is to provide a beer comprising N-acetylglucosamine or an acceptable derivative thereof.
  • Another object of the present invention is to provide a method for preparing beer, which comprises adding N-acetylglucosamine or an acceptable derivative thereof to a raw beer. Steps to prepare finished beer.
  • N-acetylglucosamine N-acetylglucosamine
  • molecular formula C 8 H 15 N0 6
  • structural formula (I) is expressed as follows:
  • liquor article acceptable derivatives include, but are not limited to: ⁇ salts formed with inorganic acids such as hydrochloride, phosphate, hydrogen phosphate, and Salts with organic acids, such as citrate, benzoate, ascorbate.
  • N-acetylglucosamine or an acceptable derivative thereof can be directly added to the raw wine to prepare a finished wine.
  • N-acetyl-D-glucosamine or an acceptable derivative thereof can be added to the raw beer as an aqueous solution.
  • N-acetyl-D-glucosamine or an acceptable derivative thereof can be packaged with the beer composition and added to the beer before the drinker drinks it.
  • the content of N-acetylglucosamine or an acceptable derivative thereof in beer can be from 0.00lg / 100ml to 100g / 100ml, and preferably from 0.00lg / 100ml to lg / 100ml.
  • N-acetylglucosamine or an acceptable derivative of alcoholic products is used as an additive in beer, which can control harmful substances such as ethanol in beer to the body, and the effective rate can reach more than 95%.
  • Proteus mirabilis should meet the following biochemical characteristics: motility (+) urease (+) lactose (-), glucose (+) H 2 S (-) 3 ⁇ 4 phenylalanine deaminase (+) ⁇ culture Base: Modified LB medium (Composition: 1% peptone, 0,5% yeast extract, 1% sodium chloride, 0.1% glucose 0J02% TTC, PH7.2-7.4) a
  • Control sample ⁇ Spot a Proteus mirabilis s 37 culture in the IL® plate 9 small test sample: Add a compound of formula (I) to a final concentration of 0.5% in the LB plate, spot a Proteus mirabilis in the same way, 37 culture 9 hour.
  • Acute toxicology test including oral, intravenous and maximum dose test
  • a commercially available beer (alcohol content 4%) was administered to a control group of mice, and the beer of the present invention (a beer alcohol content of 4% and an N-acetylglucosamine content of 0.02g / 100ml) was administered to the experimental group of mice. Gavage, the test group and the control group each 30 mice were tested. When administered at a dose of 0.2ml / 20g / times (that is, 0.2ml beer per 20g mouse weight), the rats were fed every 10 minutes. Basically fainted within 3 hours and lost consciousness; when the test group reached this dose, the state was basically normal, and individual mice showed slight standing instability. The results vary widely.
  • the drinking amount varied from 1 bottle to 4 bottles depending on the individual's usual drinking volume.
  • the test beer consisted of 0.02g / 100ml of N-acetylglucosamine added to the commercial beer, and the general response was good. 37 of them reported no dizziness, and 13 reported that the drunk response was lighter after drinking and the total effective rate was 100%.
  • N-acetylglucosamine hydrochloride was used instead of N-acetylglucosamine, and similar results were obtained.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Food Science & Technology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Non-Alcoholic Beverages (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The present provides the use of N-acetyl glucosamine or alcoholic product acceptable derivatives as additive in beer, low damaging beer that comprises N-acetyl glucosamine or alcoholic product acceptable derivatives and the method manufacturing the beer. N-acetyl glucosamine or alcoholic product acceptable derivatives as additive may can control the damage of injurious substance in the beer such as alcohol and the like to the body, the effective rate can be more than 95%.

Description

N -乙酰氨基葡萄糖作为添加剂在啤酒中的应用 及包含 N-乙酰氨基葡萄糖的啤酒 技术领域  Application of N-acetylglucosamine as an additive in beer and beer containing N-acetylglucosamine TECHNICAL FIELD
本发明涉及 N-乙酰氨基葡萄糖或其酒类制品可接受的衍生 物作为添加剂在啤酒中的应用, 包含 N-乙酰氨基葡萄糖或其酒类 制品可接受的衍生物的啤酒及制备啤酒的方法。  The present invention relates to the use of N-acetylglucosamine or an acceptable derivative thereof as an additive in beer, beer containing N-acetylglucosamine or an acceptable derivative thereof and a method for preparing beer.
技术背景  technical background
通常认为饮酒对人体的影响具有两面性。 适量饮酒可以舒筋 活血, 增加能量, 并有报道提出可对心血管疾病有防治作用。 但 所谓适量饮酒确实难以把握, 个体饮酒后反应不一。 过量饮酒的 常见症状有头晕、 头痛 眩晕、 恶心 呕吐、 食欲不正、 饮酒后 全身乏力、 口渴等外观症状; 酒精以其脂溶性和亲水性对细胞膜 脂类及膜蛋白的构型、 构象产生影响而造成对机体組织的损伤 s 大多见于肝脏和心脑血管的损伤。 人类为兼顾人们的饮酒传统习 惯和减少对人体损伤而进行了大量的探索, 但大多集中在酒制备 工艺的改造上 s 还有的是在酒中加入一些中药材 以试图改善酒 的品盾, 减少对人体影响„ The effects of drinking on the human body are generally considered to be two-sided. Moderate drinking can relax muscles and promote blood circulation, increase energy, and it has been reported that it can prevent and cure cardiovascular diseases. However, the so-called moderate drinking is indeed difficult to grasp, and individual reactions vary after drinking. Common symptoms of excessive drinking include dizziness, headache, dizziness, nausea and vomiting, appetite disorders, general weakness after drinking, thirst and other appearance symptoms; Alcohol produces cell membrane lipids and membrane proteins with its lipid-soluble and hydrophilic properties by conformation and conformation. s impact caused damage to body tissues mostly found in liver damage and cardiovascular. Human-balanced people drinking the traditional habits and reduce human injury and a lot of exploration, but mostly focused on the transformation of the preparation process of the wine s there is to add some of the herbs in the wine in an attempt to improve wine products shield, reducing the Human effects „
在酒的加工过程去除杂醇为多见的改善酒品质的方式, 但这 只是在一定程度上减少酒精以外的成份对机体的影响。 防止乙醇 对机体损伤的方法是降低乙醇的含量, 这在一定程度上起到 7一 些积极的作用。 但乙醇进入人体后特别是在其饮用量超过一定限 度时, 对机体的损伤仍然是非常明显的, 这不论在白酒、 葡萄酒 或啤酒中都是如此。  The removal of fuselage during wine processing is a common way to improve the quality of wine, but this is only to a certain extent reducing the effects of ingredients other than alcohol on the body. The way to prevent ethanol from damaging the body is to reduce the content of ethanol, which plays a positive role to some extent. However, when ethanol enters the human body, especially when the amount of alcohol consumed exceeds a certain limit, the damage to the body is still very obvious, which is true whether it is in liquor, wine or beer.
本发明人在研究工作中偶然发现, 当把 N-乙酰氨基葡萄糖或 其酒类制品可接受的衍生物以适当比例添加在啤酒中后饮用, 人 群试验反映头暈症状显著减轻, 醉酒反应不发生或增加饮用量后 推迟发生,且能有效地平緩饮用啤酒后的后续醉酒反应,如口渴、 语言表达不佳以及全身无力等不适反应。 The inventors discovered by accident in research work that when N-acetylglucosamine or an acceptable derivative of alcoholic products was added to beer in an appropriate ratio and drunk, the crowd test showed that the symptoms of dizziness were significantly reduced, and the drunken reaction did not occur. Or after drinking more Delayed occurrence, and can effectively smooth the subsequent drunk reactions after drinking beer, such as thirst, poor language expression, and general discomfort such as general weakness.
本发明人在进行生物波理论研究中建立了生物波动生长的模 型, 并进一步深入研究了生物波动生长的分子机制, 提出了生物 有机体的生物波不断改变的微异源变化原理。 生物波变化的速度 有快有慢, 取决于外来环境的改变程度。 机体接受有害物质刺激 后, 内环境出现了迅速变化, 促成微异源性发生, 使机体与环境 之间失衡, 引起局部的损伤或全身中毒症状。 这种损伤和中毒症 状的出现从分子生物学角度来分析, 是由于蛋白特别是各种酶类 在改变了的条件下, 特别是温度改变和微生物代谢产物存在条件 下, 功能不稳定甚至功能丧失。  The inventors established a model of biological wave growth in the study of biological wave theory, and further studied the molecular mechanism of biological wave growth, and proposed the principle of slightly heterogeneous changes in the biological wave of a biological organism. The speed of biological wave changes is fast or slow, depending on the degree of change in the external environment. After the body is stimulated by harmful substances, the internal environment changes rapidly, causing micro-heterogeneity to occur, causing an imbalance between the body and the environment, causing local damage or systemic poisoning symptoms. The occurrence of such damage and poisoning symptoms is analyzed from the perspective of molecular biology. It is because proteins, especially various enzymes, have unstable functions or even loss of functions under changed conditions, especially in the presence of temperature changes and microbial metabolites. .
饮酒后肝脏细胞代谢受到抑制, 非特异性炎症发生, 局部分 泌物增加 细胞肿大甚至出现混浊肿或坏死。 据信 5 N-乙酰氨基 葡萄糖作为一个生物波调控因子, 可以稳定大分子物质的振荡, 维持生理振荡不停地进行, 减緩和排斥机体存在的不利因素的影 响, 从而维持蛋白特别是各种酶类的生理功能, 减低饮酒损伤。 After drinking alcohol, liver cell metabolism is inhibited, nonspecific inflammation occurs, and local secretions increase cell swelling and even turbidity or necrosis. It is believed that 5 N-acetylglucosamine, as a biological wave regulatory factor, can stabilize the oscillation of macromolecular substances, keep the physiological oscillations ongoing, slow down and repel the effects of adverse factors in the body, and thus maintain proteins, especially various enzymes. Similar physiological functions and reduce drinking damage.
目前尚未有有欽地控制饮酒损伤的措施和药物。 在这种情况 下5 本发明人惊异地发现, N -乙酰基 氨基葡萄餹或其酒类 制品可接受的衍生物作为添加剂制备成的新型啤酒, 可有效降低 饮酒损伤。 There are currently no measures and drugs to control alcohol damage. In this case, the human 5 of the present invention surprisingly found, N - acetylglucosaminidase Tang article or alcoholic beer acceptable derivatives as novel additives prepared, the alcohol can effectively reduce injury.
发明内容  Summary of the Invention
本发明的一个目的是提供 N-乙酰氨基葡萄糖或其酒类制品 可接受的衍生物作为添加剂在啤酒中的应用。  It is an object of the present invention to provide the use of N-acetylglucosamine or an acceptable derivative thereof as an additive in beer.
本发明的另一个目的是提供包含 N-乙酰氨基葡萄糖或其酒 类制品可接受的衍生物的啤酒。  Another object of the present invention is to provide a beer comprising N-acetylglucosamine or an acceptable derivative thereof.
本发明的又一个目的是提供一种制备啤酒的方法, 包括向原 料啤酒中加入 N-乙酰氨基葡萄糖或其酒类制品可接受的衍生物 以制备成品啤酒的步骤。 Another object of the present invention is to provide a method for preparing beer, which comprises adding N-acetylglucosamine or an acceptable derivative thereof to a raw beer. Steps to prepare finished beer.
所述的 N-乙酰氨基葡萄糖的全名为 N -乙酰基 氨基葡 萄糖, 分子式为 C8H15N06, 结构式 (I )表示如下: The full name of the N-acetylglucosamine is N-acetylglucosamine, the molecular formula is C 8 H 15 N0 6 , and the structural formula (I) is expressed as follows:
Figure imgf000004_0001
Figure imgf000004_0001
可用于本发明的 N -乙酰基 - D -氨基葡萄糖的酒类制品可 接受的衍生物的实例包括但不限于: 与无机酸形成的盐 § 如盐酸 盐、 磷酸盐、 磷酸氢盐, 以及与有机酸形成的盐, 如柠橡酸盐、 苯甲酸盐、 抗坏血酸盐。 Can be used in the present invention are N - acetyl - D - glucosamine Examples liquor article acceptable derivatives include, but are not limited to: § salts formed with inorganic acids such as hydrochloride, phosphate, hydrogen phosphate, and Salts with organic acids, such as citrate, benzoate, ascorbate.
N -乙酰基 氨基葡萄糖或其酒类制品可接受的衍生物 一般可直接加入到原料畔酒中制备成成品畔酒。 或者, N -乙酰 基 - D -氨基葡萄糖或其酒类制品可接受的衍生物可以以水溶液 的形式加入到原料啤酒中。 或者, N -乙酰基 - D -氨基葡萄糖或 其酒类制品可接受的衍生物可以与啤酒组成联合包装, 在饮用者 饮用前加入到啤酒中。
Figure imgf000004_0002
Generally, N-acetylglucosamine or an acceptable derivative thereof can be directly added to the raw wine to prepare a finished wine. Alternatively, N-acetyl-D-glucosamine or an acceptable derivative thereof can be added to the raw beer as an aqueous solution. Alternatively, N-acetyl-D-glucosamine or an acceptable derivative thereof can be packaged with the beer composition and added to the beer before the drinker drinks it.
Figure imgf000004_0002
N-乙酰氨基葡萄糖或其酒类制品可接受的衍生物在啤酒中的 含量可以为 O.OOlg/lOOml至 lOg/lOOml, 优选为 O.Olg/lOOml至 lg/100ml„ N-乙酰氨基葡萄糖或其酒类制品可接受的衍生物作为添加剂 应用于啤酒中, 可控制啤酒中乙醇等有害物质对机体的损害, 有 效率可达 95%以上。 The content of N-acetylglucosamine or an acceptable derivative thereof in beer can be from 0.00lg / 100ml to 100g / 100ml, and preferably from 0.00lg / 100ml to lg / 100ml. N-acetylglucosamine or an acceptable derivative of alcoholic products is used as an additive in beer, which can control harmful substances such as ethanol in beer to the body, and the effective rate can reach more than 95%.
具体实施方式  detailed description
下面结合实施例进一步说明本发明及其有益效果, 但是应该 明白, 这些实施例仅是为了举例说明本发明, 而不在任何方面构 成对本发明范围的限制。  The present invention and its beneficial effects are further described below with reference to the examples, but it should be understood that these examples are only for the purpose of illustrating the present invention and do not limit the scope of the present invention in any respect.
实施例 1. 式 (I )化合物的促波试验  Example 1. Wave-promoting test of a compound of formula (I)
1、 试驗材料和方法:  1.Test materials and methods:
1.1 样品: 式 ( I )化合物纯品。  1.1 Sample: Pure compound of formula (I).
1.2 试验材料:  1.2 Test materials:
菌种: 奇异变形杆菌应符合如下生化反应特征: 动力 (+) 尿 素酶 (+) 乳糖(-)、 葡萄糖 (+) H2S( - )¾ 苯丙氨酸脱氨酶 (+)β 培养基: 改良 LB培养基(组成成分: 1 %踉蛋白胨、 0,5%酵 母提取物、 1 %氯化钠、 0.1%葡萄糖 0J02%TTC、 PH7.2-7.4 )a Bacterial strains: Proteus mirabilis should meet the following biochemical characteristics: motility (+) urease (+) lactose (-), glucose (+) H 2 S (-) ¾ phenylalanine deaminase (+) β culture Base: Modified LB medium (Composition: 1% peptone, 0,5% yeast extract, 1% sodium chloride, 0.1% glucose 0J02% TTC, PH7.2-7.4) a
1.3 试验方法:  1.3 Test method:
对照样: 在 IL®平板中 ^点种奇异变形杆菌 s 37 培养 9小 试验样: 在 LB平板中加入终浓度为 0.5%的式 ( I )化合物, 同法点种奇异变形杆菌, 37 培养 9小时。 Control sample: ^ Spot a Proteus mirabilis s 37 culture in the IL® plate 9 small test sample: Add a compound of formula (I) to a final concentration of 0.5% in the LB plate, spot a Proteus mirabilis in the same way, 37 culture 9 hour.
2、 试验结果及评价:  2. Test results and evaluation:
在对照样中显示出不断向外扩展, 间隔 3小时的同心环; 在 试验样中, 不但形成每隔 3小时出现的同心环, 而且与对照相比, 在每条环上显示出许多细小的波动环。  In the control sample, concentric rings that continuously expand outward are displayed at intervals of 3 hours. In the test sample, not only are concentric rings that appear every 3 hours, but compared with the control, many small rings are displayed on each ring. Fluctuation ring.
本试验采用生物波波动试臉模型, 用以研究式(I )化合物的 促波作用, 结果可见式(I )化合物不仅可以使细菌细胞表现正常 的生物波特征, 而且使这种波动表现出更加微细的波动方式, 表 明式(I )化合物对生物波动是有促进作用的。 这种促波作用有助 于解释 N-乙酰氨基葡萄糖或其酒类制品可接受的衍生物控制饮 酒后损伤的效果。 In this test, a biological wave wave test model was used to study the wave-promoting effect of the compound of formula (I). As a result, it can be seen that the compound of formula (I) can not only make bacterial cells show normal biological wave characteristics, but also make this wave show more Subtle fluctuations, table The compound of the formula (I) has a promoting effect on biological fluctuations. This wave-promoting effect helps explain the effect of N-acetylglucosamine or an acceptable derivative thereof in controlling damage after drinking.
实施例 2. 式 (I )化合物的毒理试验  Example 2. Toxicological test of compound of formula (I)
进行式 (I )化合物的毒理试验, 包括:  Conducting a toxicological test of a compound of formula (I), including:
1、 急性毒理试验: 包括口服、 静脉注射和最大极限量给药试 验;  1. Acute toxicology test: including oral, intravenous and maximum dose test;
2、 Ames试验;  2. Ames test;
3、 小鼠骨髓细胞微核试验;  3. Micronucleus test of mouse bone marrow cells;
4、 鼠精子畸性试验;  4. Rat sperm abnormality test;
5、 小鼠睾丸染色体畸变试验;  5. Test for chromosomal aberrations in mice;
6、 慢性致死试验;  6. Chronic lethal test;
7¾ 亚慢性毒性(9 天喂养) 试验; 7 ¾ subchronic toxicity (9-day feeding) test;
8, 传统致畸试验;  8, traditional teratogenic test;
试验结论表明: 式 (Ϊ )化合物急性毒性试验剂量超过 /kg 时, 仍未出现急性中毒反应; 在长期毒性试验中, 最高剂量已达 到 lg/kg, 经四周试验观察5 未出现中毒反应; 在生殖试验中 5 从常规剂量 7mg/kg喂小鼠, 经三次传代, 证明式 (I )化合物对 小鼠受孕、 妊娠、 分娩、 哺乳及仔鼠发育均无影响。 这些试验证 明式 ( I )化合物属无毒物质。 实施例 3. 动物试验 The test results show that: when the acute toxicity test dose of the compound of formula (Ϊ) exceeds / kg, no acute poisoning reaction has yet occurred; in the long-term toxicity test, the highest dose has reached lg / kg, and no toxicity reaction has occurred after 5 weeks of observation; In the fertility test, 5 mice were fed with a conventional dose of 7 mg / kg, and after three passages, it was proved that the compound of formula (I) had no effect on mouse conception, pregnancy, childbirth, lactation and pup development. These tests prove that the compounds of formula (I) are non-toxic. Example 3. Animal test
采用市售的啤酒 (酒精度 4% )对对照组小白鼠进行灌胃, 采用本发明的啤酒 (啤酒酒精度 4%和 N-乙酰氨基葡萄糖的含量 0.02g/100ml ) 对试验组小白鼠进行灌胃, 试验組和对照组各 30 只小白鼠进行试验。 当以 0.2ml/20g/次 (即每次 20克小鼠体重灌 0.2ml啤酒)的剂量灌胃,每 10分钟加喂一次, 结果对照组小鼠在 3 小时内基本上晕厥, 失去知觉; 试验组达到此剂量时状态均基 本上正常, 个别鼠出现轻微的站立不稳的状态。 结果差别较大。 实施例 4.人群饮用试验 A commercially available beer (alcohol content 4%) was administered to a control group of mice, and the beer of the present invention (a beer alcohol content of 4% and an N-acetylglucosamine content of 0.02g / 100ml) was administered to the experimental group of mice. Gavage, the test group and the control group each 30 mice were tested. When administered at a dose of 0.2ml / 20g / times (that is, 0.2ml beer per 20g mouse weight), the rats were fed every 10 minutes. Basically fainted within 3 hours and lost consciousness; when the test group reached this dose, the state was basically normal, and individual mice showed slight standing instability. The results vary widely. Example 4. Crowd drinking test
50例人体试用, 饮用量根据个人平时饮酒量分别为 1瓶至 4 瓶不等。 试验啤酒组成为市售啤酒中添加 N-乙酰氨基葡萄糖 0.02g/100ml,普遍反应较好, 其中有 37人反映不头暈, 13人反映 饮酒后醉酒反应较轻, 总有效率 100%。  In 50 human trials, the drinking amount varied from 1 bottle to 4 bottles depending on the individual's usual drinking volume. The test beer consisted of 0.02g / 100ml of N-acetylglucosamine added to the commercial beer, and the general response was good. 37 of them reported no dizziness, and 13 reported that the drunk response was lighter after drinking and the total effective rate was 100%.
该试验中,采用 N-乙酰氨基葡萄糖盐酸盐代替 N-乙酰氨基葡 萄糖, 取得相似结果。  In this test, N-acetylglucosamine hydrochloride was used instead of N-acetylglucosamine, and similar results were obtained.

Claims

权 利 要 求 Rights request
1. N-乙酰氨基葡萄糖或其酒类制品可接受的衍生物作为添加 剂在啤酒中的应用。 1. Use of N-acetylglucosamine or an acceptable derivative of alcoholic beverage as an additive in beer.
2. 权利的要求 1的应用, 其中将 N-乙酰氨基葡萄糖或其酒类 制品可接受的衍生物加入酒体中制备成新型酒品。  2. The use according to claim 1, wherein N-acetylglucosamine or an acceptable derivative thereof is added to the wine body to prepare a new type of wine.
3. 权利的要求 1的应用, 其中在饮用啤酒前将 N-乙酰氨基葡 萄糖或其酒类制品可接受的衍生物加入啤酒中。  3. Use according to claim 1, wherein N-acetylglucosamine or an acceptable derivative thereof is added to the beer before drinking the beer.
4. 权利要求 1-3中任一项的应用, 其中 N-乙酰氨基葡萄糖或 其酒类制品可接受的衍生物在啤酒中的含量为 O.OOlg/lOOml 至 lOg/lOOmlo  The use according to any one of claims 1 to 3, wherein the content of N-acetylglucosamine or an acceptable derivative thereof in beer is from 0.0000 g / 100 ml to 100 g / 100 ml
5. 权利要求 4的应用, 其中 N-乙酰氨基葡萄糖或其酒类制品 可接受的衍生物在啤酒中的含量为 OJlg/1歸腿 I至 lg/1歸讓 I。 5. The use according to claim 4, wherein the content of the acceptable derivative of N-acetylglucosamine or its alcoholic beverage in beer ranges from OJlg / 1 to I to lg / 1 to I.
6. 包含 -乙酰氨基葡萄糖或其酒类制品可接受的衍生物的啤 酒。 6. Beer containing -acetylglucosamine or an acceptable derivative of its alcoholic beverage.
7. 权利要求 6的啤酒, 其中 N-乙酰氨基葡萄糖或其酒类制品 可接受的衍生物在啤酒中的含量为 J01g/1 腿 I至 lOg/10®腿 L §. 权利要求 7的啤酒, 其中 N-乙酰氨基葡萄糖或其酒类制品 可接受的衍生物在啤酒中的含量为 O.Olg/lOOml至 lg/100mlo 9. 一种制备啤酒的方法, 包括向原料啤酒中加入 N-乙酰氨基 葡萄糖或其酒类制品可接受的衍生物以制备成品啤酒的步骤。  7. The beer of claim 6, wherein the content of N-acetylglucosamine or an acceptable derivative thereof in the beer is J01g / 1 leg I to 10g / 10® leg L §. The beer of claim 7, Wherein the content of N-acetylglucosamine or an acceptable derivative of the alcoholic product in beer is from 0.01 to 100 ml / lOOml / 100ml to lg / 100mlo. 9. A method for preparing beer, comprising adding N-acetylamino to raw beer A step in which glucose or an acceptable derivative thereof is used to prepare a finished beer.
PCT/CN2004/000277 2003-03-27 2004-03-29 The use of n-acetyl glucosamine as additive in beer and beer comprising n-acetyl glucosamine WO2004085603A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN03108276.9 2003-03-27
CNA031082769A CN1534088A (en) 2003-03-27 2003-03-27 Application of N-acetylglucosamine as additive in beer and beer containing N-acetylglucosamine

Publications (1)

Publication Number Publication Date
WO2004085603A1 true WO2004085603A1 (en) 2004-10-07

Family

ID=33035132

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2004/000277 WO2004085603A1 (en) 2003-03-27 2004-03-29 The use of n-acetyl glucosamine as additive in beer and beer comprising n-acetyl glucosamine

Country Status (2)

Country Link
CN (1) CN1534088A (en)
WO (1) WO2004085603A1 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1611895A4 (en) * 2003-03-27 2008-02-20 Univ Pla 3Rd Military Medical Use of n-acetyl-d-aminoglycosamine in treatment of organ lesions related to toxicosis of drugs or chemicals
WO2009007660A1 (en) 2007-07-04 2009-01-15 Mathieu Borge Liquid or paste compositions intended to provide elements essential for the synthesis and formation of proteoglycans, in particular, for the treatment of cartilage degradation

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102234601B (en) * 2010-04-23 2014-12-24 桂太容 Application of oligo-fructose, mannose and derivatives thereof in preparation of functional low-harm wines and anti-inebriation products
CN112375633A (en) * 2020-11-26 2021-02-19 江苏双林海洋生物药业有限公司 Glucosamine wine and preparation method thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1156175A (en) * 1996-12-27 1997-08-06 中国人民解放军第三军医大学 Health-care wine using N-acetyl-D-aminoglucose as additives

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1156175A (en) * 1996-12-27 1997-08-06 中国人民解放军第三军医大学 Health-care wine using N-acetyl-D-aminoglucose as additives

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
HUANG GUANG-FU ET AL.: "The advance of polysaccharide biomedical materials chitin and chitosan", CHINESE BULLETIN OF MACROMOLECULE, no. 3, 2001, pages 43 - 49 *
LU YONG-ZHANG: "Magic chitoson", JIANGXI CHEMICAL INDUSTRY, no. 3, 1997, pages 34 - 35 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1611895A4 (en) * 2003-03-27 2008-02-20 Univ Pla 3Rd Military Medical Use of n-acetyl-d-aminoglycosamine in treatment of organ lesions related to toxicosis of drugs or chemicals
WO2009007660A1 (en) 2007-07-04 2009-01-15 Mathieu Borge Liquid or paste compositions intended to provide elements essential for the synthesis and formation of proteoglycans, in particular, for the treatment of cartilage degradation

Also Published As

Publication number Publication date
CN1534088A (en) 2004-10-06

Similar Documents

Publication Publication Date Title
Horwitz et al. Monoamine oxidase inhibitors, tyramine, and cheese
WO2009021399A1 (en) Biotoxin adsorbent and its producing process
MX2011007550A (en) Clay interlaced yeast compositions and methods of utilizing the same.
AU2002318969B2 (en) A composition and uses therefor for combating hangover
EP3230256A1 (en) Alcoholic beverage substitutes
WO2004085603A1 (en) The use of n-acetyl glucosamine as additive in beer and beer comprising n-acetyl glucosamine
AU2002318969A1 (en) A composition and uses therefor for combating hangover
NZ509221A (en) An additive containing a mineral clay and a modified yeast cell wall extract for reduction of effects of endophyte-infected forages
JP2013124243A (en) Agent for suppressing elevation of blood alcohol concentration
WO2004085604A1 (en) The use of n-acetyl glucosamine as additive in wine and wine comprising n-acetyl glucosamine
Timiras et al. Lifetime brain serotonin: regional effects of age and precursor availability
US9168274B1 (en) Method to reduce intoxication from ethanol in humans
WO2004084916A1 (en) Use of acetyl-d-aminoglycosamine in treatment of local lesions and systematic symptoms related to infections of virus or bacteria
JP5192108B2 (en) Composition for inhibiting methanogenesis and composition for feed for ruminants
WO2010027014A1 (en) Method for improving absorption of s-adenosyl-l-methionine, and composition having improved s-adenosyl-l-methionine absorption
WO2004093556A1 (en) The use of n-acetyl glucosamine as additive in milk products
US9441210B2 (en) Method of reducing levels of uric acid
JP7011347B2 (en) A composition for relieving a hangover or a composition for preventing, ameliorating or treating alcoholic liver disease containing beta-glucan as an active ingredient.
US20080227869A1 (en) Substituted nitrobenzene derivatives as pharmaceutical and other uses thereof
JP4852218B2 (en) Alcohol metabolism promoter composition
JPH04230628A (en) Use of ten-memberedring lactone as lipid adjusting drug
JPH10295393A (en) Production of vitamin k
JPH1070960A (en) Use of selenium-containing microbial cell
US11278516B2 (en) Medicinal compositions of cannabinoids and xanthines
EP3357541B1 (en) Methylsulfonylmethane composition for reducing blood alcohol content

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase